ID: ALA5291429

Max Phase: Preclinical

Molecular Formula: C12H6Cl2N6OS2

Molecular Weight: 385.26

Associated Items:

Representations

Canonical SMILES:  O=C(Nc1cnccn1)c1nnc(Sc2c(Cl)cncc2Cl)s1

Standard InChI:  InChI=1S/C12H6Cl2N6OS2/c13-6-3-16-4-7(14)9(6)22-12-20-19-11(23-12)10(21)18-8-5-15-1-2-17-8/h1-5H,(H,17,18,21)

Standard InChI Key:  RDJFHTLZSZHENW-UHFFFAOYSA-N

Associated Targets(Human)

USP7 Tchem Ubiquitin carboxyl-terminal hydrolase 7 (837 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 385.26Molecular Weight (Monoisotopic): 383.9422AlogP: 3.43#Rotatable Bonds: 4
Polar Surface Area: 93.55Molecular Species: NEUTRALHBA: 8HBD: 1
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.29CX Basic pKa: 1.06CX LogP: 2.24CX LogD: 2.24
Aromatic Rings: 3Heavy Atoms: 23QED Weighted: 0.74Np Likeness Score: -1.98

References

1. Li P, Liu HM..  (2020)  Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.,  191  [PMID:32092586] [10.1016/j.ejmech.2020.112107]

Source